243 related articles for article (PubMed ID: 18410567)
1. Developments in the therapeutic use of erythropoiesis stimulating agents.
Jelkmann W
Br J Haematol; 2008 May; 141(3):287-97. PubMed ID: 18410567
[TBL] [Abstract][Full Text] [Related]
2. Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma.
Katodritou E; Terpos E; Zervas K; Speletas M; Kapetanos D; Kartsios C; Verrou E; Banti A; Effraimidou S; Christakis J
Ann Hematol; 2007 May; 86(5):369-76. PubMed ID: 17375302
[TBL] [Abstract][Full Text] [Related]
3. Nononcologic use of human recombinant erythropoietin therapy in hospitalized patients.
Fischer MA; Morris CA; Winkelmayer WC; Avorn J
Arch Intern Med; 2007 Apr; 167(8):840-6. PubMed ID: 17452549
[TBL] [Abstract][Full Text] [Related]
4. Stimulating erythropoiesis: future perspectives.
Mikhail A; Covic A; Goldsmith D
Kidney Blood Press Res; 2008; 31(4):234-46. PubMed ID: 18587242
[TBL] [Abstract][Full Text] [Related]
5. Triumph and tragedy: anemia management in chronic kidney disease.
Novak JE; Szczech LA
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
[TBL] [Abstract][Full Text] [Related]
6. Risks and benefits of erythropoiesis-stimulating agents in cancer management.
Beutel G; Ganser A
Semin Hematol; 2007 Jul; 44(3):157-65. PubMed ID: 17631180
[TBL] [Abstract][Full Text] [Related]
7. The potential of erythropoietin and related strategies to stimulate erythropoiesis.
Eckardt KU
Curr Opin Investig Drugs; 2001 Aug; 2(8):1081-5. PubMed ID: 11892917
[TBL] [Abstract][Full Text] [Related]
8. Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients.
Reuter SE; Faull RJ; Ranieri E; Evans AM
Nephrol Dial Transplant; 2009 Mar; 24(3):990-6. PubMed ID: 18987259
[TBL] [Abstract][Full Text] [Related]
9. Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications.
Gascón P
Oncologist; 2008; 13 Suppl 3():4-10. PubMed ID: 18458118
[TBL] [Abstract][Full Text] [Related]
10. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
Aapro MS; Link H
Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
[TBL] [Abstract][Full Text] [Related]
11. Treatment options for anemia, taking risks into consideration: erythropoiesis-stimulating agents versus transfusions.
Spano JP; Khayat D
Oncologist; 2008; 13 Suppl 3():27-32. PubMed ID: 18458122
[TBL] [Abstract][Full Text] [Related]
12. Thrombotic complications of erythropoiesis-stimulating agents.
Lippi G; Franchini M; Favaloro EJ
Semin Thromb Hemost; 2010 Jul; 36(5):537-49. PubMed ID: 20632251
[TBL] [Abstract][Full Text] [Related]
13. Novel erythropoiesis-stimulating agents: a new era in anemia management.
Macdougall IC
Clin J Am Soc Nephrol; 2008 Jan; 3(1):200-7. PubMed ID: 18077782
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study.
Ludwig H; Aapro M; Bokemeyer C; Macdonald K; Soubeyran P; Turner M; Albrecht T; Abraham I
Eur J Cancer; 2009 Jun; 45(9):1603-15. PubMed ID: 19278851
[TBL] [Abstract][Full Text] [Related]
15. The role of recombinant erythropoietin in childhood cancer.
Shankar AG
Oncologist; 2008 Feb; 13(2):157-66. PubMed ID: 18305061
[TBL] [Abstract][Full Text] [Related]
16. 2009: a requiem for rHuEPOs--but should we nail down the coffin in 2010?
Goldsmith D
Clin J Am Soc Nephrol; 2010 May; 5(5):929-35. PubMed ID: 20413441
[TBL] [Abstract][Full Text] [Related]
17. The role of recombinant human erythropoietin in the management of anaemic cancer patients: focus on haematological malignancies.
Osterbor A
Med Oncol; 2000 Nov; 17 Suppl 1():S17-22. PubMed ID: 11188781
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of anaemia in patients with malignancy: implications for the clinical use of recombinant human erythropoietin.
Cazzola M
Med Oncol; 2000 Nov; 17 Suppl 1():S11-6. PubMed ID: 11188780
[TBL] [Abstract][Full Text] [Related]
19. Inflammation and resistance to erythropoiesis-stimulating agents--what do we know and what needs to be clarified?
Smrzova J; Balla J; Bárány P
Nephrol Dial Transplant; 2005 Sep; 20 Suppl 8():viii2-7. PubMed ID: 16079326
[TBL] [Abstract][Full Text] [Related]
20. Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease.
Bárány P; Müller HJ
Nephrol Dial Transplant; 2007 Jun; 22 Suppl 4():iv10-iv18. PubMed ID: 17526545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
